Durvalumab and olaparib combination extends survival in advanced endometrial cancer
Updated Phase 3 DUO-E trial results presented at ESMO 2026 show that durvalumab plus olaparib after chemotherapy achieved a median ...
Updated Phase 3 DUO-E trial results presented at ESMO 2026 show that durvalumab plus olaparib after chemotherapy achieved a median ...
A real-world cohort study of 327 patients with EGFR-mutated non-small cell lung cancer finds that continuing EGFR-TKI therapy plus anti-angiogenic ...
A retrospective study of 339 non-diabetic gastric cancer patients found that a high postoperative glucose-to-lymphocyte ratio and low visceral fat ...
A retrospective three-center study of 156 patients shows that a new ABT score, built from the alkaline phosphatase to prealbumin ...
Sequencing of tumor tissue from 107 glioma patients reveals microbial signatures linked to tumor grade and survival, with predicted metabolic ...
A multi-cohort re-analysis of melanoma transcriptomes and single-cell immune data links coordinated checkpoint-gene expression to longer overall survival, treatment-related immune ...
A Swedish multicenter retrospective study of 29 patients suggests that shortening the period of concomitant azacitidine, venetoclax and gilteritinib exposure ...
A retrospective study of 247 gastric cancer patients aged 75 and older finds that chronological age is not an independent ...
A network meta-analysis of six randomized trials in 5,838 patients finds that pembrolizumab plus belzutifan offers the strongest protection against ...
Experimental p300 inhibition reduced breast cancer cell survival and spread, while cytoplasmic localization in patient tumors was associated with lower ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine